HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Cox, C. D. Articles by Tsikouris, J. P. Search for Related Content PubMed PubMed Citation Articles by Cox, C. D. Articles by Tsikouris, J. P.

Preventing Contrast Nephropathy: What Is the Best Strategy? A Review of the Literature

From Texas Tech University Health Sciences Center, School of Pharmacy, Lubbock, Texas.

Patients receiving radiocontrast for diagnostic and interventional procedures are at risk for developing contrast nephropathy (CN). In fact, radiocontrast nephropathy is currently the third leading cause of hospital-acquired renal failure. Understanding that CN has been associated with increased length of hospitalization and mortality, determining the best prevention strategy is of utmost importance. Patients at the greatest risk for developing acute renal failure are patients with diabetes and underlying renal insufficiency. Several therapies have been investigated for the prevention of CN; unfortunately, very few have shown a consistent benefit. Therapies that have been studied include saline hydration, N-acetylcysteine (NAC), theophylline, calcium channel blockers, diuretics, dopamine, endothelin receptor antagonists, atrial natriuretic peptide, angiotensin-converting enzyme inhibitors, and prostaglandin E-1. Using adequate hydration, using low-osmolar dyes, and minimizing the dose of contrast have all been shown to be effective in reducing CN and are considered the standard of care. While trials with many pharmacologic agents have produced conflicting results, intervention with NAC has also been promising. This article reviews the pathophysiology, risk factors, and therapies that are currently available for the prevention of CN.

Key Words: N-acetylcysteine (NAC) • contrast nephropathy • acute renal failure • prevention • risk factors

Address for reprints: Craig D. Cox, PharmD, BCPS, Assistant Professor of Pharmacy Practice, Texas Tech University School of Pharmacy, 3601 4th Street, Suite 1C162, Lubbock, TX 79430.

This article has been cited by other articles:

				R Mathew, K Haque, and W Woothipoom Acute renal failure induced by contrast medium: steps towards prevention. BMJ, September 9, 2006; 333(7567): 539 - 540. [Full Text] [PDF]

				T. Schachner, J. Bonatti, N. Bonaros, R. Poeltl, G. Feuchtner, G. Laufer, O. Pachinger, and G. Friedrich Risk factors of postoperative nephropathy in patients undergoing innovative CABG and intraoperative graft angiography. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 431 - 435. [Abstract] [Full Text] [PDF]

				S. Detrenis, M. Meschi, S. Musini, and G. Savazzi Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1542 - 1550. [Full Text] [PDF]

				I. Goldenberg and S. Matetzky Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies Can. Med. Assoc. J., May 24, 2005; 172(11): 1461 - 1471. [Abstract] [Full Text] [PDF]

				A. Asif, D. L. Epstein, and M. Epstein Dopamine-1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast-Induced Nephropathy J. Clin. Pharmacol., December 1, 2004; 44(12): 1342 - 1351. [Abstract] [Full Text] [PDF]